

VWA9 siRNA (m): sc-108608

BACKGROUND

VWA9 (von Willebrand factor A domain containing 9), also known as C15orf44, is a 518 amino acid protein that contains one VWFA domain and is strongly expressed in cancer cells, including lung, prostate, colon, stomach and skin, as compared to their non-cancerous counterparts. Existing as four alternatively spliced isoforms, VWA9 is encoded by a gene that maps to human chromosome 15q22.31. Encoding more than 700 genes, chromosome 15 is made up of approximately 106 million base pairs and makes up approximately 3% of the human genome. Angelman and Prader-Willi syndromes are associated with loss of function or deletion of genes in the 15q11-q13 region. Tay-Sachs disease is a lethal disorder associated with mutations of the HEXA gene, which is encoded by chromosome 15. Marfan syndrome is associated with chromosome 15 through the FBN1 gene.

REFERENCES

1. Cachón-González, M.B., Wang, S.Z., Lynch, A., Ziegler, R., Cheng, S.H. and Cox, T.M. 2006. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. *Proc. Natl. Acad. Sci. USA* 103: 10373-10378.
2. Zody, M.C., Garber, M., Sharpe, T., Young, S.K., Rowen, L., O'Neill, K., Whittaker, C.A., Kamal, M., Chang, J.L., Cuomo, C.A., Dewar, K., Fitzgerald, M.G., Kodira, C.D., Madan, A., Qin, S., Yang, X., Abbasi, N., et al. 2006. Analysis of the DNA sequence and duplication history of human chromosome 15. *Nature* 440: 671-675.
3. Diene, G., Postel-Vinay, A., Pinto, G., Polak, M. and Tauber, M. 2007. The Prader-Willi syndrome. *Ann. Endocrinol.* 68: 129-137.
4. Lalande, M. and Calciano, M.A. 2007. Molecular epigenetics of Angelman syndrome. *Cell. Mol. Life Sci.* 64: 947-960.
5. Maegawa, G.H., Tropak, M., Buttner, J., Stockley, T., Kok, F., Clarke, J.T. and Mahuran, D.J. 2007. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. *J. Biol. Chem.* 282: 9150-9161.
6. Makoff, A.J. and Flomen, R.H. 2007. Detailed analysis of 15q11-q14 sequence corrects errors and gaps in the public access sequence to fully reveal large segmental duplications at breakpoints for Prader-Willi, Angelman, and inv dup(15) syndromes. *Genome Biol.* 8: R114.
7. Ramirez, F. and Dietz, H.C. 2007. Fibrillin-rich microfibrils: structural determinants of morphogenetic and homeostatic events. *J. Cell. Physiol.* 213: 326-330.
8. ten Dijke, P. and Arthur, H.M. 2007. Extracellular control of TGF β signalling in vascular development and disease. *Nat. Rev. Mol. Cell Biol.* 8: 857-869.

CHROMOSOMAL LOCATION

Genetic locus: Vwa9 (mouse) mapping to 9 C.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

VWA9 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see VWA9 shRNA Plasmid (m): sc-108608-SH and VWA9 shRNA (m) Lentiviral Particles: sc-108608-V as alternate gene silencing products.

For independent verification of VWA9 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-108608A, sc-108608B and sc-108608C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

VWA9 siRNA (m) is recommended for the inhibition of VWA9 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor VWA9 gene expression knockdown using RT-PCR Primer: VWA9 (m)-PR: sc-108608-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.